Supplementary Table 2.
Clinical success definition in each included study
| Author, year | Intervention | Total (n) | Clinical success | Clinical success definition |
|---|---|---|---|---|
| Pai et al., 2015 | EUS-RFA | 2 | 2 | Central area of necrosis on follow-up cross-sectional imaging and change in vascularity |
| Lakhtakia et al., 2016 | EUS-RFA | 3 | 3 | All functioning, symptom resolution |
| Choi et al., 2018 | EUS-RFA | 8 | 6 | Absence of enhancing tissue at tumor site on contrast-enhanced CT or EUS on follow-up |
| De La Sena et al., 2018 | EUS-RFA | 3 | 1 | CT shows well-defined nonenhancing area and EUS with hyperechogenic area with absence of malignant tissue after FNA |
| Thosani et al., 2018 | EUS-RFA | 3 | 3 | All functioning, symptom resolution |
| Fathima et al., 2019 | EUS-RFA | 18 | 15 | Symptom resolution for functioning and decrease in size for nonfunctioning |
| De Nucci et al., 2019 | EUS-RFA | 11 | 11 | Complete disappearance of lesions and symptom resolution |
| Oleinikov et al., 2019 | EUS-RFA | 25 | 25 | Presence of nonenhancing area (central necrosis) at the site of ablated lesion on CECT, fibrotic tissue on the site of ablated lesion on EUS, and loss of uptake on PET/CT |
| Dancour et al., 2019 | EUS-RFA | 8 | 8 | All functioning, symptom resolution |
| Barthet et al., 2019 | EUS-RFA | 14 | 12 | Disappearance of lesion |
| Trosic-Ivanisevic et al., 2019 | EUS-RFA | 7 | 6 | Disappearance of lesion and symptom resolution |
| Younis et al., 2019 | EUS-RFA | 3 | NR | Not applicable |
| Malikowski et al., 2020 | EUS-RFA | 8 | 8 | Good sonographic response and complete ablation |
| Levy et al., 2012 | EUS-EA | 5 | 3 | All functioning, symptom resolution |
| Park et al., 2015 | EUS-EA | 14 | 9/13 | Disappearance of enhanced area within the tumors based on contrast-enhanced CT or EUS on follow-up |
| Yang et al., 2015 | EUS-EA | 4 | 3 | All functioning, symptom resolution |
| Qin et al., 2016 | EUS-EA | 17 | 17 | All functioning, symptom resolution |
| Paik et al., 2016 | EUS-EA | 6 | 5 | Complete ablation on imaging or the absence of hormone-related symptoms |
| Choi et al., 2018 | EUS-EA | 40 | 24 | Absence of enhanced area within the tumors based on repeat imaging and negative cytology on EUS-FNB at 3-year follow-up |
| Matsumoto et al., 2020 | EUS-EA | 5 | 4 | Absence of enhanced area on follow-up CT every 3 months |
RFA: Radiofrequency ablation; EA: Ethanol ablation; CT: Computed tomography; CECT: Contrast-enhanced CT; FNB: Fine-needle biopsy; NR: Not reported, PET: Positron emission tomography